Biogen has completed the acquisition of Human Immunology Biosciences, a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases. Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy study and from the completed Phase 2 antibody-mediated rejection study. These data were presented at the European Renal Association Congress and also published in the New England Journal of Medicine. Felzartamab has also demonstrated proof-of-concept in a Phase 2 study in primary membranous nephropathy and there are plans to advance felzartamab to Phase 3 in AMR, IgAN, and PMN. Felzartamab is an investigational therapeutic candidate that has not yet been approved by any regulatory authority and its safety and effectiveness have not been established.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen Completes Acquisition of Human Immunology Biosciences
- Biogen’s Lecanemab launched in China to treat Alzheimer’s Disease
- Biogen’s Lecanemab launched in China to treat Alzheimer’s Disease Use symbol Eisai
- “LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China
- RBC believes Leqembi on track for EU approval after speaking to Biogen